U.S. flag

An official website of the United States government

NM_000492.4(CFTR):c.3038C>T (p.Pro1013Leu) AND not specified

Germline classification:
Uncertain significance (1 submission)
Last evaluated:
Jul 30, 2024
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV001255508.3

Allele description [Variation Report for NM_000492.4(CFTR):c.3038C>T (p.Pro1013Leu)]

NM_000492.4(CFTR):c.3038C>T (p.Pro1013Leu)

Genes:
CFTR:CF transmembrane conductance regulator [Gene - OMIM - HGNC]
LOC111674472:DNase I hypersensitive sites in introns 16 and 17a of CFTR [Gene]
Variant type:
single nucleotide variant
Cytogenetic location:
7q31.2
Genomic location:
Preferred name:
NM_000492.4(CFTR):c.3038C>T (p.Pro1013Leu)
HGVS:
  • NC_000007.14:g.117610568C>T
  • NG_016465.4:g.149785C>T
  • NG_056128.2:g.3622C>T
  • NM_000492.4:c.3038C>TMANE SELECT
  • NP_000483.3:p.Pro1013Leu
  • NP_000483.3:p.Pro1013Leu
  • LRG_663t1:c.3038C>T
  • LRG_663:g.149785C>T
  • LRG_663p1:p.Pro1013Leu
  • NC_000007.13:g.117250622C>T
  • NM_000492.3:c.3038C>T
  • P13569:p.Pro1013Leu
Protein change:
P1013L
Links:
UniProtKB: P13569#VAR_000230; dbSNP: rs193922516
NCBI 1000 Genomes Browser:
rs193922516
Molecular consequence:
  • NM_000492.4:c.3038C>T - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Synonyms:
AllHighlyPenetrant
Identifiers:
MedGen: CN169374

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV001431941Women's Health and Genetics/Laboratory Corporation of America, LabCorp
criteria provided, single submitter

(LabCorp Variant Classification Summary - May 2015)
Uncertain significance
(Jul 30, 2024)
germlineclinical testing

PubMed (18)
[See all records that cite these PMIDs]

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening.

Bobadilla JL, Macek M Jr, Fine JP, Farrell PM.

Hum Mutat. 2002 Jun;19(6):575-606. Review.

PubMed [citation]
PMID:
12007216

Analysis of the CFTR gene in Turkish cystic fibrosis patients: identification of three novel mutations (3172delAC, P1013L and M1028I).

Onay T, Topaloglu O, Zielenski J, Gokgoz N, Kayserili H, Camcioglu Y, Cokugras H, Akcakaya N, Apak M, Tsui LC, Kirdar B.

Hum Genet. 1998 Feb;102(2):224-30.

PubMed [citation]
PMID:
9521595
See all PubMed Citations (18)

Details of each submission

From Women's Health and Genetics/Laboratory Corporation of America, LabCorp, SCV001431941.3

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (18)

Description

Variant summary: CFTR c.3038C>T (p.Pro1013Leu) results in a non-conservative amino acid change located in the ABC transporter type 1, transmembrane domain (IPR011527) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 3.2e-05 in 251138 control chromosomes. c.3038C>T has been reported in the literature in the compound heterozygous state or an unknown state in multiple individuals affected with clinical features of Cystic Fibrosis and/or testing positive for CF upon NBS (example, Onay_1998, Kilinc_2002, Elahi_2006, Narzi_2007, Schippa_2013, Lucarelli_2015, Castaldo_2020, Bozdogan_2021, Erdoan_2021, Saferali_2022), including at least 1 family where 2 siblings carried a pathogenic variant in trans segregating with disease. These data indicate that the variant may be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect resulted in approximately 30.71% of normal chloride channel conductance relative to wild type (e.g., Bihler_2024). The following publications have been ascertained in the context of this evaluation (PMID: 12007216, 33572515, 32784480, 11504857, 16436643, 34860163, 11278813, 34426522, 12439892, 25880441, 25910067, 17594398, 9521595, 25735457, 34996830, 23613805, 26437683, 38388235). ClinVar contains an entry for this variant (Variation ID: 53634). Based on the evidence outlined above, the variant was classified as VUS-possibly pathogenic.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024